Balaji Amines Limited
Momentum (93/100) does the heavy lifting; valuation (3/100) is the drag.
ExpensiveOvervaluedStocksWizard rates Balaji Amines Limited a Hold, scoring 45/100 on our blended model. We put fair value near ₹1,079.29; at ₹2,133.3 that leaves roughly 49% downside, so the stock screens overvalued by 49%. On 42.1x trailing earnings it sits pricier than the Basic Materials median of about 22.2x. The price is about 12% below its 52-week high of ₹2,414.9 and 119% above the low of ₹972.38. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹2,085.67 implies about 2% downside across 3 analysts. It clears 8 of 13 investability checks, with durability 66, valuation 5 and momentum 93 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹863.44.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-11.66% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 8.1%
- Pass: Low debt (D/E < 0.5): 0.06x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 12%
- Pass: Earnings growing: 62%
- Pass: Net margin ≥ 10%: 11.7%
- Pass: Current ratio > 1.5: 2.34
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 8.81
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter67.6%
- Institutions2.3%
- Public & other30.1%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 8.81.
Opportunities
- Earnings growing (62% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~49% above our estimated fair value.
About Balaji Amines Limited
Balaji Amines Limited manufactures and sells methylamines, ethylamines, and specialty chemicals along with pharma excipients across India and internationally. The company operates through two segments: Chemicals and Hotel. Its chemical offerings include monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, dimethyl and diethyl amino ethanol, and specialty chemicals such as N-methyl pyrrolidone and morpholine.
Balaji Amines Limited — frequently asked questions
Is Balaji Amines Limited a buy, hold or sell?
StocksWizard currently rates Balaji Amines Limited (BALAMINES) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Balaji Amines Limited's fair value?
Our blended DCF and relative-valuation model estimates Balaji Amines Limited's fair value at about ₹1,079.29, versus a current price of ₹2,133.3 — roughly 49% downside. On that basis the stock looks overvalued by 49%.
Is Balaji Amines Limited financially healthy?
Balaji Amines Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Balaji Amines Limited's share price performed?
Balaji Amines Limited is up 47% over three months, and last traded at ₹2,133.3. Past performance doesn't predict future returns.
More in Basic Materials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.